Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$69.60
-2.2%
$70.78
$61.24
$87.68
$215.85B0.375.25 million shs6.77 million shs
Bay National Co. stock logo
BAYN
Bay National
$0.01
$0.01
$0.01
$0.01
N/A1.56510 shs10,200 shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$38.26
-0.6%
$38.99
$31.72
$44.67
$78.33B0.54.93 million shs3.00 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$15.89
+1.3%
$14.80
$11.51
$21.50
$2.77B0.52101,418 shs59,320 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
-2.15%-0.67%-3.09%+1.67%-9.38%
Bay National Co. stock logo
BAYN
Bay National
0.00%0.00%0.00%0.00%0.00%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-0.67%-0.87%-5.44%+4.84%-0.47%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
+1.30%+3.61%+8.12%+10.53%-9.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.3624 of 5 stars
2.43.01.70.02.80.01.3
Bay National Co. stock logo
BAYN
Bay National
N/AN/AN/AN/AN/AN/AN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.171 of 5 stars
1.14.02.50.01.90.02.5
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1.6434 of 5 stars
2.04.00.00.01.10.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.83
Moderate Buy$85.0022.13% Upside
Bay National Co. stock logo
BAYN
Bay National
0.00
N/AN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.10
Hold$37.38-2.31% Downside
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.00
Hold$19.0019.54% Upside

Current Analyst Ratings Breakdown

Latest AZN, GSK, BAYN, HCM, and DPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/13/2025
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
4/28/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
4/15/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
4/15/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$35.25
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B3.99$6.16 per share11.30$13.18 per share5.28
Bay National Co. stock logo
BAYN
Bay National
N/AN/AN/AN/AN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$40.10B1.95$5.54 per share6.90$8.07 per share4.74
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$630.20M4.40$0.29 per share54.62$4.43 per share3.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.4927.9513.921.3114.14%33.14%12.83%7/24/2025 (Estimated)
Bay National Co. stock logo
BAYN
Bay National
N/AN/A0.00N/AN/AN/AN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$3.29B$1.9419.728.231.559.89%48.82%11.15%7/30/2025 (Estimated)
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$37.73MN/A0.0010.89N/AN/AN/AN/AN/A

Latest AZN, GSK, BAYN, HCM, and DPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.12N/AN/AN/A$7.92 billionN/A
7/24/2025Q2 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.11N/AN/AN/AN/AN/A
4/30/2025Q1 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion
4/29/2025Q1 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10$1.24+$0.14$0.93$13.71 billion$13.59 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$2.062.96%N/A82.73%N/A
Bay National Co. stock logo
BAYN
Bay National
N/AN/AN/AN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.694.42%N/A87.11%N/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A

Latest AZN, GSK, BAYN, HCM, and DPH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42164.1%5/16/20255/16/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.65
0.90
0.70
Bay National Co. stock logo
BAYN
Bay National
N/AN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.21
0.87
0.58
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.08
2.83
2.70

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Bay National Co. stock logo
BAYN
Bay National
N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Bay National Co. stock logo
BAYN
Bay National
17.76%
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
Bay National Co. stock logo
BAYN
Bay National
N/AN/AN/ANot Optionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
68,6292.05 billion1.84 billionOptionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,811174.32 million168.05 millionNot Optionable

Recent News About These Companies

HUTCHMED to Announce 2025 Half-Year Financial Results
HUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by Wall Street Zen
HUTCHMED (China) Limited (HCM.L) - Yahoo Finance
HUTCHMED (China) Limited (HCM) - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?
Hutchmed introduces new share options and LTIP awards

New MarketBeat Followers Over Time

Media Sentiment Over Time

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$69.60 -1.53 (-2.15%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$69.64 +0.04 (+0.06%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Bay National stock logo

Bay National OTCMKTS:BAYN

$0.01 0.00 (0.00%)
As of 07/21/2021

Bay National Corp. operates as a bank holding company. It offers loans, deposits, investments and other banking and financial services through its subsidiary, Bay National Bank. The company was founded in 1999 and is headquartered in Lutherville, MD.

GSK stock logo

GSK NYSE:GSK

$38.26 -0.25 (-0.65%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$38.28 +0.02 (+0.04%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$15.89 +0.20 (+1.30%)
Closing price 07/3/2025 01:18 PM Eastern
Extended Trading
$15.94 +0.04 (+0.26%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.